α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson's Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Smith, Lynnae M ^a   Schiess, Mya C ^b   Coffey, Mary P ^a   Klaver, Andrea C ^a   Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN ANTIBODY; ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ATYPICAL PARKINSON SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MALE; PARASOMNIA; PARKINSON DISEASE; PARKINSONISM; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER;

EID: 84871324721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052285     Document Type: Article

References (43)

1. Wakabayashi K, Tanji K, Mori F, Takahashi H, (2007) The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27: 494-506.
2. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
3. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
4. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
5. Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171.
6. Jellinger KA, (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18: S2-S12.
7. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884.
8. Sidhu A, Wersinger C, Moussa CE, Vernier P, (2004) The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 1035: 250-270.
9. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571-576.
10. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945-1947.
11. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65-67.
12. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, et al. (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75: 1766-1772.
13. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20: 419-425.
14. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55-59.
15. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, et al. (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480: 78-82.
16. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, et al. (2006) The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 113: 1435-1439.
17. Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, et al. (2007) Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 204: 583-588.
18. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, et al. (2010) Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord 25: 489-493.
19. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, et al. (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230-240.
20. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, et al. (2011) Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 25: 4127-4137.
21. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW, (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J Clin Neurol 7: 215-222.
22. Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, et al. (2002) Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 58: 1435-1436.
23. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, et al. (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101: 749-756.
24. Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, et al. (2011) Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol 233: 221-227.
25. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, et al. (2011) α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 6: e18513.
26. Gruden MA, Yanamandra K, Kucheryanu VG, Bocharova OR, Sherstnev VV, et al. (2012) Correlation between Protective Immunity to α-Synuclein Aggregates, Oxidative Stress and Inflammation. Neuroimmunomodulation 19: 334-342.
27. Schenck CH, Bundlie SR, Mahowald MW, (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46: 388-393.
28. Iranzo A, (2011) Sleep-wake changes in the premotor stage of Parkinson disease. J Neurol Sci 310: 283-285.
29. Jankovic J, (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79: 368-376.
30. Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park: Macmillan. 153-163.
31. Hoehn M, Yahr M, (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
32. Patrias LM, Klaver AC, Coffey MP, Loeffler DA, (2010) Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. Clin Exp Immunol 161: 527-535.
33. SAS Institute (2008) The SAS System for Windows, version 9.2. Cary, NC.
34. Hintze J (2011) PASS11. NCSS, LLC, Kaysville, Utah, USA. www.ncss.com.
35. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, et al. (2011) Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord 31: 413-416.
36. Schrag A, Schott JM, (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5: 355-363.
37. Smith LM, Klaver AC, Coffey MP, Dang L, Loeffler DA, (2012) Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. Int Immunopharmacol 14: 550-557.
38. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, et al. (2011) Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 26: 171-179.
39. Woulfe J, Hoogendoorn H, Tarnopolsky M, Muñoz DG, (2000) Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain. Neurology 55: 1398-1401.
40. Bartels T, Choi JG, Selkoe DJ, (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477: 107-110.
41. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, et al. (2012) Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J Biol Chem 287: 15345-15364.
42. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868.
43. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6: e19338.